Informations générales (source: ClinicalTrials.gov)
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
Interventional
Phase 2
Bristol-Myers Squibb (Voir sur ClinicalTrials)
août 2019
août 2029
02 octobre 2025
Main Objective of this study is to examine long-term safety of nivolumab monotherapy
including combinations and other cancer therapies in various tumor types.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Christos CHOUAID | 06/05/2024 13:54:03 | Contacter | ||
| CLCC INSTITUT GUSTAVE ROUSSY | Caroline ROBERT | 29/05/2024 15:58:06 | Contacter | ||
| HOPITAL FOCH | Christine ABRAHAM | 20/10/2025 07:25:38 | Contacter | ||
Critères
Tous
- Signed Written Informed Consent.
- Eligible to receive continued study treatment per the Parent Study, including
treatment beyond progression per investigator assessment in the Parent Study.
- On treatment hold in the Parent Study following long-lasting response or are
eligible for treatment rechallenge as defined in the Parent Study.
- WOCBP and male participants who are sexually active must agree to follow
instructions for method(s) of contraception as described below and included in the
ICF.
Exclusion Criteria:
- Participant is not eligible for study treatment per the Parent Study eligibility
criteria.
- Participants not receiving clinical benefit as assessed by the Investigator.
- Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness
which, in the opinion of the Investigator, indicates that participation in the study
is not in the best interest of the participant.
- Other protocol-defined Inclusion/Exclusion Criteria apply